Database release
Added entries:
- (FDA) KRAS p.G12C and sensitivity to adagrasib in combination with cetuximab for patients with colorectal cancer received accelerated approval.
- (FDA) NTRK1/2/3 gene fusions and sensitivity to repotrectinib for patients with solid tumors received accelerated approval.
Revised entries:
- (FDA) RET fusions and sensitivity to selpercatinib for patients with thyroid cancer received traditional approval from the FDA, from accelerated approval.